When compared with placebo, vunakizumab is a safe and efficacious treatment for moderate to severe plaque psoriasis among adults.

And beyond the physical symptoms, plaque psoriasis also frequently has negative effects on mental health and alters the ...

The efficacy and safety of risankizumab remains similar across racial and ethnic groups of patients with moderate to severe plaque psoriasis.

Eli Lilly has dropped (PDF) the lead candidate from its $2.4 billion takeover of Dice Thera | Eli Lilly has dropped the lead candidate from its $2.4 billion takeover of Dice Therapeutics, shifting the ...

J&J said its latest TV ad, which highlights the psoriasis experience among people of color, is part of its broader effort to ...

Johnson & Johnson (NYSE: JNJ) announced today that treatment with TREMFYA® (guselkumab) resulted in clear or almost clear ...

Phase 3b trial evaluating Tremfya (guselkumab) in low body surface area plaque psoriasis found the treatment improved clearance.

New phase 3b data reveal significant skin clearance in historically underserved patients with moderate plaque psoriasis, offering hope for improved treatment outcomes.

Hidradenitis suppurativa (HS) is an inflammatory, chronic disease with very high symptom and physical burdens, and it can get ...

cream for adults with moderate to severe chronic hand eczema (CHE), the filing of a New Drug Application (NDA) for ...

(RTTNews) - Johnson & Johnson (JNJ) Friday announced positive results from Phase 3b SPECTREM study of Tremfya to treat adults with low body surface area (BSA) moderate plaque psoriasis (PsO) in ...

Tremfya is approved for the treatment of adults with moderate to severe plaque psoriasis who may benefit from systemic therapy or phototherapy. The views and opinions expressed herein are the ...